Prognostic Significance of Ground-glass Areas Within Tumours in Non-small-cell Lung Cancer

Overview

Journal Eur J Cardiothorac Surg

Publisher Oxford University Press

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2024 Apr 10

PMID 38598462

Authors

Hiroyuki Sakurai

Yasushi Goto

Kiyotaka Yoh

Kazuya Takamochi

Takehiro Shukuya

Tomoyuki Hishida

Masahiro Tsuboi

Koichi Yoshida

Yasuhisa Ohde

Sakae Okumura

Masataka Taguri

Hideo Kunitoh

Affiliations

Soon will be listed here.

Abstract

Objectives: To validate or refute the hypothesis that non-small-cell lung cancers (NSCLC) with ground-glass areas (GGA+) within the tumour on high-resolution computed tomography are associated with a more favourable prognosis than those without GGA (GGA-).

Methods: We analysed data from a multicentre observational cohort study in Japan including 5005 patients with completely resected pathological stage I NSCLC, who were excluded from the Japan Clinical Oncology Group (JCOG) 0707 trial on oral adjuvant treatment during the enrolment period. The patients' medical and pathological records were assessed retrospectively by physicians and re-staged according to the 8th tumour, node, metastasis edition.

Results: Of the 5005 patients, 2388 (48%) were ineligible for the JCOG0707 trial and 2617 (52%) were eligible but were not enrolled. A total of 958 patients (19.1%) died. Patients with GGA+ NSCLC and pathological invasion ≤3 cm showed significantly better overall survival than others. In patients with tumours with an invasive portion ≤4 cm, GGA+ was associated with better survival. The prognoses of patients with GGA+ T2a and GGA- T1c tumours were similar (5-year overall survival: 84.6% vs 83.1%, respectively). The survival with T2b or more tumours appeared unaffected by GGA, and GGA was not prognostic in these larger tumours.

Conclusions: Patients with GGA+ NSCLC on high-resolution computed tomography and ≤4 cm invasion size may have a better prognosis than patients with solid GGA- tumours of the same T-stage. However, the presence or absence of radiological GGA has little impact on the prognosis of patients with NSCLC with greater (>4 cm) pathological invasion.

References

Ding H, Wang H, Zhang P, Song N, Chen L, Jiang G . Prognostic factors of lung adenocarcinoma manifesting as ground glass nodules larger than 3 cm. Eur J Cardiothorac Surg. 2018; 55(6):1130-1135. DOI: 10.1093/ejcts/ezy422. View

Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S . Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification. J Thorac Oncol. 2017; 12(9):1403-1412. DOI: 10.1016/j.jtho.2017.06.003. View

Sakurai H, Nakagawa K, Watanabe S, Asamura H . Clinicopathologic features of resected subcentimeter lung cancer. Ann Thorac Surg. 2015; 99(5):1731-8. DOI: 10.1016/j.athoracsur.2015.01.034. View

Shuster J . Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1):191-2. DOI: 10.1200/JCO.1991.9.1.191. View

Yip R, Li K, Liu L, Xu D, Tam K, Yankelevitz D . Controversies on lung cancers manifesting as part-solid nodules. Eur Radiol. 2017; 28(2):747-759. PMC: 5996385. DOI: 10.1007/s00330-017-4975-9. View

Tsuboi M, Herbst R, John T, Kato T, Majem M, Grohe C . Overall Survival with Osimertinib in Resected -Mutated NSCLC. N Engl J Med. 2023; 389(2):137-147. DOI: 10.1056/NEJMoa2304594. View

Asamura H, Nakayama H, Kondo H, Tsuchiya R, NARUKE T . Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg. 1999; 117(6):1102-11. DOI: 10.1016/s0022-5223(99)70246-1. View

Ye T, Deng L, Wang S, Xiang J, Zhang Y, Hu H . Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. J Thorac Oncol. 2019; 14(4):617-627. DOI: 10.1016/j.jtho.2018.12.030. View

Shukuya T, Takamochi K, Sakurai H, Yoh K, Hishida T, Tsuboi M . Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy. JTO Clin Res Rep. 2022; 3(5):100320. PMC: 9117917. DOI: 10.1016/j.jtocrr.2022.100320. View

10.

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K . Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399(10335):1607-1617. DOI: 10.1016/S0140-6736(21)02333-3. View

11.

Eba J, Nakamura K . Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol. 2022; 52(6):539-544. PMC: 9157286. DOI: 10.1093/jjco/hyac034. View

12.

Kunitoh H, Tsuboi M, Wakabayashi M, Okada M, Suzuki K, Watanabe S . A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707). JTCVS Open. 2022; 4:90-102. PMC: 9390442. DOI: 10.1016/j.xjon.2020.08.009. View

13.

Heidinger B, Anderson K, Moriarty E, Costa D, Gangadharan S, VanderLaan P . Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology Correlation. Acad Radiol. 2017; 24(7):851-859. DOI: 10.1016/j.acra.2017.01.009. View

14.

Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K . Neither Maximum Tumor Size nor Solid Component Size Is Prognostic in Part-Solid Lung Cancer: Impact of Tumor Size Should Be Applied Exclusively to Solid Lung Cancer. Ann Thorac Surg. 2016; 102(2):407-15. DOI: 10.1016/j.athoracsur.2016.02.074. View

15.

Hattori A, Hirayama S, Matsunaga T, Hayashi T, Takamochi K, Oh S . Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma. J Thorac Oncol. 2018; 14(2):265-275. DOI: 10.1016/j.jtho.2018.09.026. View

16.

Shin K, Cho S, Chung J, Lee K, Lee C, Kim K . Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size. Ann Thorac Surg. 2017; 103(5):1654-1660. DOI: 10.1016/j.athoracsur.2016.10.040. View

17.

Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H . Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg. 2006; 81(2):413-9. DOI: 10.1016/j.athoracsur.2005.07.058. View

18.

Asamura H, Hishida T, Suzuki K, Koike T, Nakamura K, Kusumoto M . Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg. 2013; 146(1):24-30. DOI: 10.1016/j.jtcvs.2012.12.047. View

19.

Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H . Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan. Jpn J Clin Oncol. 2018; 49(1):63-68. DOI: 10.1093/jjco/hyy165. View

20.

Watanabe S, Asamura H . Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol. 2009; 4(5):652-7. DOI: 10.1097/JTO.0b013e31819cce50. View